PUBLIC COMPANY
save$TNGXTango Therapeutics, Inc.
$TNGX24.42+0.49%Boston, MA, USupdated 16h ago
community read0 votes
pipeline
3
marketed
0
phase 3
0
catalysts ytd
2
approvals ytd
0
recalls ytd
0
Pipeline(3)
pipeline depth3 products
3Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (1)
Active trials
- phase2Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
- phase2Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
- phase2Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors
- phase2Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- phase2Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
- phase2Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors
Insider activity
source: SEC Form 4open-market buys + sells
- Apr 15, 26SELLCrystal Adam· President, R&D−$962K↗
routine RSU / option mechanics (2)
- Apr 15, 26option exerciseCrystal Adam · President, R&D38,460 sh
- Apr 15, 26option exerciseCrystal Adam · President, R&D38,460 sh
🐶 Hiring Signal
Where Tango Therapeutics, Inc. is staffing up — a leading indicator of pipeline and commercial priorities.
therapeutic areaOncology 18
News
- Lilly offers up to $1B for Alzheimer's drug; Bial cuts failed Parkinson's drugPlus news about Parabilis Medicines, RA Capital, Tango Therapeutics, Ideaya Biosciences, Bavarian Nordic and Cartesian Therapeutics 💸 Lilly’s $1B Alzheimer’s deal: The Indianapolis drugmaker will…endpoints · 3mo ago
Data sources
last refreshed 57m ago
Found something off?
comments(0)
5-min edit window · permanent after that